Biology of Reproduction, Vol 52, 824-832, Copyright © 1995 by Society for the Study of Reproduction

ARTICLES

Estrogen-induced guinea pig model for uterine leiomyomas: do the ovaries protect?

KB Porter, JC Tsibris, SV Nicosia, JM Murphy, WF O'Brien, PS Rao and WN Spellacy
Department of Obstetrics and Gynecology, University of South Florida, Tampa 33606, USA.

A guinea pig model was used to study the hormonal control of uterine leiomyomas. Twenty female guinea pigs were divided into four groups-- young, old, ovariectomized (OVX), and non-OVX animals--and were given two estradiol-17 beta (E2) silastic implants each for 3-10 mo; another four older OVX animals served as controls and received empty implants. After 3 mo, 100% (8 of 8) of the OVX animals, but none of the OVX controls, developed tumors, mainly on the uterine serosa and the abdominal wall. Electron microscopy and desmin immunostaining demonstrated that the tumors were leiomyomas. In E2-treated animals, E2 levels in serum, leiomyomas, or leiomyoma-free uterine segments rose significantly while serum progesterone (P4) was negligible. Surprisingly, only 8% (1 of 12) of the non-OVX animals developed a tumor. This apparent "ovarian protection" was transient: after 6-9 mo, 50% of the remaining non-OVX animals developed leiomyomas, but these were smaller and fewer than in OVX animals. On the basis of this model, we propose the hypothesis that some factors from the ovaries suppress leiomyoma growth in response to estrogen but that as the ovaries age this protection is diminished, allowing the clinical development of leiomyomas.

This article has been cited by other articles:

				M. A. Behera, L. Feng, B. Yonish, W. Catherino, S.-H. Jung, and P. C. Leppert Thrombospondin-1 and Thrombospondin-2 mRNA and TSP-1 and TSP-2 Protein Expression in Uterine Fibroids and Correlation to the Genes COL1A1 and COL3A1 and to the Collagen Cross-link Hydroxyproline Reproductive Sciences, December 1, 2007; 14(8_suppl): 63 - 76. [Abstract] [PDF]

				B. Eskenazi, M. Warner, S. Samuels, J. Young, P. M. Gerthoux, L. Needham, D. Patterson, D. Olive, N. Gavoni, P. Vercellini, et al. Serum Dioxin Concentrations and Risk of Uterine Leiomyoma in the Seveso Women's Health Study Am. J. Epidemiol., July 1, 2007; 166(1): 79 - 87. [Abstract] [Full Text] [PDF]

				R. R. Newbold, A. B. Moore, and D. Dixon Characterization of Uterine Leiomyomas in CD-1 Mice Following Developmental Exposure to Diethylstilbestrol (DES) Toxicol Pathol, August 1, 2002; 30(5): 611 - 616. [Abstract] [PDF]

				J. C. M. Tsibris, K. B. Porter, A. Jazayeri, G. Tzimas, H. Nau, H. Huang, K. Kuparadze, G. W. Porter, W. F. O'Brien, and W. N. Spellacy Human Uterine Leiomyomata Express Higher Levels of Peroxisome Proliferator-activated Receptor {{gamma}}, Retinoid X Receptor {{alpha}}, and all-trans Retinoic Acid Than Myometrium Cancer Res., November 1, 1999; 59(22): 5737 - 5744. [Abstract] [Full Text] [PDF]